

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant:

Yoav KIMCHY

Serial No.: 10/616,301

Filed: July 10, 2003

For: INGESTIBLE PILL

Examiner:



Group Art Unit: 3736

Attorney
Docket: 25854

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.


This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

Sol Sheinbein
Registration No. 25,457

Date: November 25, 2003

Please type a plus sign (+) inside this box → +



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)

Approved for use through 10/31/99 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/616,301
Sheet	2	Of	2	Filing Date	07/10/2003
				First Named Inventor	Kimchy
				Group Art Unit	3736
				Examiner Name	
Sheet	2	Of	2	Attorney Docket Number	25854
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
		Mettler et al, "Essentials of Nuclear Medicine Imaging", Pub.: WB Saunders, Chap. 14.			
		Piperno et al, "Breast Cancer Screening by Impedance Measurements", <i>Frontiers Med. Biol. Engng.</i> , 2(2):11-17, 1990			
		Rajshekhar, V., "Continuous Impedance Monitoring During CT-Guided Stereotactic Surgery: Relative Value in Cystic and Solid Lesions", <i>British Journal of Neurosurgery</i> , 6:439-444, 1992			
		Jessup, JM, "Tumor Markers – Prognostic and Therapeutic Implications for Colorectal Carcinoma", <i>Surgical Oncology</i> , 7:139-151, 1998			
		Corstens et al, "Nuclear Medicine's Role in Infection and Inflammation", <i>The Lancet</i> , 354:765-770, 1999			
		Mori et al, "Overexpression of Matrix Metalloproteinase-7mRNA in Human Colon Carcinomas", <i>Cancer</i> , 75:1516-1519, 1995			
		Erbil et al, "Use and Limitations of Serum Total and Lipid-Bound Sialic Acid Concentrations as Markers for Colorectal Cancer", <i>Cancer</i> , 55:404-409, 1985			
		Molinolo et al, "Enhanced Tumor Binding Using Immunohistochemical Analyses by Second Generation Anti-Tumor-Associated Glycoprotein 72 Monoclonal Antibodies versus Monoclonal Antibody B72.3 in Human Tissue", <i>Cancer Research</i> , 50:1291-1298, 1990			
		Day et al, "Localization of Radioiodinated Rat Fibrogen in Transplanted Rat Tumors", <i>J. Nat. Cancer Inst.</i> , 23:799-812, 1959			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹. Unique citation designation number. ². Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.